Generic Name: Neoral
What is Neoral?
Using additional drugs that treat organ transplant rejection may increase these tendencies. Certain brands of Sandimmum Neoral Cyclospotine must not be used with other immunosuppressants. Sandimmum Neoral Cyclospotine can also cause high blood pressure and kidney problems. The risk of both problems increase with increasing dose and length of therapy. Psoriasis patients who have had certain previous treatments e. Therefore, Sandimmun Neoral Cyclosporine must be given only under close medical supervision.
In kidney, liver, or heart transplant patients, Neoral more. Brabourne Pharmaceuticals Sandimmun Neoral Capsules Sandimmun neoral 100 mg Cyclosporine Capsules lowers your body's immune system. The immune system helps your body fight infections.
Valspodar is a cyclosporine analog with less renal and immunosuppressive effects than cyclosporine while retaining effects on MDR. The addition of cyclosporine or valspodar to daunorubicin therapy may result in increases in AUC for both daunorubicin and daunorubincinol possibly due to a decrease in clearance of parent drug, a decrease in metabolism of daunorubincinol, or an increase in intracellular daunorubicin concentrations.
Daunorubicin: Concurrent use of daunorubicin with other agents which cause bone marrow or immune suppression such as other immunosuppressives may result in additive effects. This effect may be even more pronounced in patients. Although not specifically studied, reduced serum concentrations may also occur in patients taking other CYP3A4 substrates such as cyclosporine. If these drugs are used together, monitor patients for a decrease in the effects of cyclosporine. Deferoxamine: Although not specifically studied, reduced serum concentrations of deferoxamine may occur in patients taking other CYP3A4 substrates such as cyclosporine.
In addition, coadministration of deferasirox with other potentially nephrotoxic drugs, including cyclosporine, may increase the risk of acute renal failure. Deflazacort: Decrease deflazacort dose to one third of the recommended dosage when coadministered with cyclosporine.
Concurrent use may significantly increase concentrations of 21-desDFZ, the active metabolite of deflazacort, resulting in an increased risk of toxicity. Administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Delavirdine: Delavirdine is a potent inhibitor of the CYP3A4 and increased plasma concentrations of drugs extensively metabolized by this enzyme, such as cyclosporine, should be expected with concurrent use of delavirdine.
How should I take Neoral?
Ketorolac: Additive decreases in renal function have been reported between cyclosporine and nonsteroidal anti-inflammatory drugs. Lanreotide: Coadministration with lanreotide may decrease the bioavailability of cyclosporine. Lapatinib: Lapatinib is a CYP3A4 substrate and a CYP3A4 inhibitor at clinically relevant concentrations in vitro. Both ledipasvir and cyclosporine are substrates and inhibitors of the drug transporter P-glycoprotein P-gp.
Taking these drugs together may increase plasma concentrations of both drugs.
What should I avoid while taking Neoral?
Deflazacort: Decrease deflazacort dose to one third of the recommended dosage when coadministered with cyclosporine. Concurrent use may significantly increase concentrations of 21-desDFZ, the active metabolite of deflazacort, resulting in an increased risk of toxicity. Administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Delavirdine: Delavirdine is a potent inhibitor of the CYP3A4 and increased plasma concentrations of drugs extensively metabolized by this enzyme, such as cyclosporine, should be expected with concurrent use of delavirdine.
If metabolic acidosis occurs or persists, consider reducing the dose or discontinuing dichlorphenamide therapy. Significant interactions may occur between cyclosporine and NSAIDs. Clinical status and serum creatinine and potassium concentrations should be closely monitored when cyclosporine is given with salicylates or other nonsteroidal antiinflammatory drugs NSAIDs.
Neoral side effects
Special caution should be observed if Neoral is used in combination with methotrexate due to nephrotoxic synergy. Additional precautions in psoriasisDiscontinuation of Neoral therapy is recommended if hypertension developing during treatment cannot be controlled with appropriate therapy. Elderly patients should be treated only in the presence of disabling psoriasis, and renal function should be monitored with particular care. There is only limited experience with the use of Neoral in children with psoriasis.
In psoriatic patients on ciclosporin, as in those on conventional immunosuppressive therapy, development of malignancies in particular of the skin has been reported. Skin lesions not typical for psoriasis, but suspected to be malignant or pre-malignant should be biopsied before Neoral treatment is started.
Common Neoral ide effects may include:
Zileuton: Zileuton is a CYP3A4 inhibitor and may decrease the clearance of cyclosporine, with the potential to reduce cyclosporine dosage requirements or cause cyclosporine toxicity.
The mechanism has not been established but is thought to be due to inhibition of cyclosporine metabolism.
This formulation uses a lipid emulsion base instead of cremophor and ethanol.
Pharmacodynamic interactions have been reported between cyclosporine and NSAIDs, consisting of additive decreases in renal function with concomitant use.
Do not use potassium-containing salt substitutes while taking Sandimmun-Neoral Cyclosporine 100mg. Consult your doctor or pharmacist for more information. Using other drugs that treat organ transplant rejection along with Sandimmun-Neoral Cyclosporine 100mg may increase these tendencies.
Sandimmun-Neoral Cyclosporine 100mg can also cause high blood pressure and kidney problems. The risk of both problems increases with higher doses and longer treatment with Sandimmun-Neoral Cyclosporine 100mg.
Where can I get more information?
It is used to prevent the rejection of organ transplants and bone marrow transplants by suppressing the body's natural defence, the immune system.
Cyclosporine is a substrate and inhibitor of P-glycoprotein, which is an energy-dependent drug-efflux pump located in intestinal epithelium and the blood brain barrier.